- Home
- DIAX vs FULC Comparison
DIAX vs FULC Comparison
Compare DIAX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- FULC
- Stock Information
- Founded
- DIAX 2005
- FULC 2015
- Country
- DIAX United States
- FULC United States
- Employees
- DIAX N/A
- FULC N/A
- Industry
- DIAX Finance Companies
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- DIAX Finance
- FULC Health Care
- Exchange
- DIAX Nasdaq
- FULC Nasdaq
- Market Cap
- DIAX 535.3M
- FULC 469.0M
- IPO Year
- DIAX N/A
- FULC 2019
- Fundamental
- Price
- DIAX $14.81
- FULC $7.65
- Analyst Decision
- DIAX
- FULC Buy
- Analyst Count
- DIAX 0
- FULC 7
- Target Price
- DIAX N/A
- FULC $10.43
- AVG Volume (30 Days)
- DIAX 96.6K
- FULC 631.8K
- Earning Date
- DIAX 01-01-0001
- FULC 10-29-2025
- Dividend Yield
- DIAX 7.93%
- FULC N/A
- EPS Growth
- DIAX N/A
- FULC N/A
- EPS
- DIAX N/A
- FULC N/A
- Revenue
- DIAX N/A
- FULC N/A
- Revenue This Year
- DIAX N/A
- FULC N/A
- Revenue Next Year
- DIAX N/A
- FULC N/A
- P/E Ratio
- DIAX N/A
- FULC N/A
- Revenue Growth
- DIAX N/A
- FULC 2752.05
- 52 Week Low
- DIAX $12.80
- FULC $2.32
- 52 Week High
- DIAX $15.12
- FULC $10.11
- Technical
- Relative Strength Index (RSI)
- DIAX 52.18
- FULC 39.22
- Support Level
- DIAX $14.73
- FULC $8.42
- Resistance Level
- DIAX $14.94
- FULC $9.47
- Average True Range (ATR)
- DIAX 0.14
- FULC 0.78
- MACD
- DIAX -0.00
- FULC -0.25
- Stochastic Oscillator
- DIAX 50.52
- FULC 14.95
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.